Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dhawan, P.
Right arrow Articles by Richmond, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dhawan, P.
Right arrow Articles by Richmond, A.
(Journal of Leukocyte Biology. 2002;72:9-18.)
© 2002 by Society for Leukocyte Biology

Role of CXCL1 in tumorigenesis of melanoma

Punita Dhawan* and Ann Richmond*,{dagger}

{dagger} Department of Veterans Affairs, Nashville, Tennessee; and
* Department of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee

Correspondence: Ann Richmond, Department of Cancer Biology, Vanderbilt University School of Medicine, MCN T-2212, Nashville, TN 37232. E-mail: ann.richmond{at}mcmail.vanderbilt.edu

The CXC chemokine, CXCL1 (melanoma growth-stimulatory activity/growth-regulated protein {alpha}), plays a major role in inflammation, angiogenesis, tumorigenesis, and wound healing. Recently, chemokines have been extensively related to cellular transformation, tumor growth, homing, and metastasis. CXCL1 and its mouse homologue MIP-2 have been shown to be involved in the process of tumor formation. When chemokines such as CXCL1 and CXCL8 (IL-8) become disregulated so that they are chronically expressed, tissue damage, angiogenesis, and tumorigenesis can follow. This up-regulation of chemokines has been attributed to constitutive activation of NF-{kappa}B. The constitutive NF-{kappa}B activation is an emerging hallmark in various types of tumors including breast, colon, pancreatic, ovarian, as well as melanoma. Previous findings from our laboratory and other laboratories have demonstrated the role of endogenous activation of NF-{kappa}B in association with enhanced metastatic potential of malignant melanoma cells and suggest that targeting NF-{kappa}B may have potential therapeutic effects in clinical trials. An important step in this direction would be to delineate the important intracellular pathways and upstream kinases involved in up-regulation of NF-{kappa}B in melanoma cells. In this review, the signaling pathways involved in the disregulation of NF-{kappa}B and chemokine expression are discussed.

Key Words: chemokines • NF-{kappa}B • signaling




This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
M. Schon, B. G. Wienrich, S. Kneitz, H. Sennefelder, K. Amschler, V. Vohringer, O. Weber, T. Stiewe, K. Ziegelbauer, and M. P. Schon
KINK-1, a Novel Small-Molecule Inhibitor of IKK{beta}, and the Susceptibility of Melanoma Cells to Antitumoral Treatment
J Natl Cancer Inst, June 18, 2008; 100(12): 862 - 875.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
B. E. Bachmeier, I. V. Mohrenz, V. Mirisola, E. Schleicher, F. Romeo, C. Hohneke, M. Jochum, A. G. Nerlich, and U. Pfeffer
Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NF{kappa}B
Carcinogenesis, April 1, 2008; 29(4): 779 - 789.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Bakalian, J.-C. Marshall, P. Logan, D. Faingold, S. Maloney, S. Di Cesare, C. Martins, B. F. Fernandes, and M. N. Burnier Jr.
Molecular Pathways Mediating Liver Metastasis in Patients with Uveal Melanoma
Clin. Cancer Res., February 15, 2008; 14(4): 951 - 956.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Richmond
CCR9 Homes Metastatic Melanoma Cells to the Small Bowel
Clin. Cancer Res., February 1, 2008; 14(3): 621 - 623.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
P. Ribaux, J. A. Ehses, N. Lin-Marq, F. Carrozzino, M. Boni-Schnetzler, E. Hammar, J.-C. Irminger, M. Y. Donath, and P. A. Halban
Induction of CXCL1 by Extracellular Matrix and Autocrine Enhancement by Interleukin-1 in Rat Pancreatic {beta}-Cells
Endocrinology, November 1, 2007; 148(11): 5582 - 5590.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Wen, S. F. Giardina, D. Hamming, J. Greenman, E. Zachariah, M. D. Bacolod, H. Liu, J. Shia, P. S. Amenta, F. Barany, et al.
GRO{alpha} Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1.
Clin. Cancer Res., October 15, 2006; 12(20): 5951 - 5959.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Rutella, G. Bonanno, A. Procoli, A. Mariotti, D. G. de Ritis, A. Curti, S. Danese, G. Pessina, S. Pandolfi, F. Natoni, et al.
Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features
Blood, July 1, 2006; 108(1): 218 - 227.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
T. Kakinuma and S. T. Hwang
Chemokines, chemokine receptors, and cancer metastasis
J. Leukoc. Biol., April 1, 2006; 79(4): 639 - 651.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. Zhou, J. Zhang, Q. Liu, R. Bell, D. A. Muruve, P. Forsyth, M. Arcellana-Panlilio, S. Robbins, and V.W. Yong
The chemokine GRO-{alpha} (CXCL1) confers increased tumorigenicity to glioma cells
Carcinogenesis, December 1, 2005; 26(12): 2058 - 2068.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Milyavsky, Y. Tabach, I. Shats, N. Erez, Y. Cohen, X. Tang, M. Kalis, I. Kogan, Y. Buganim, N. Goldfinger, et al.
Transcriptional Programs following Genetic Alterations in p53, INK4A, and H-Ras Genes along Defined Stages of Malignant Transformation
Cancer Res., June 1, 2005; 65(11): 4530 - 4543.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
Q.-J. Li, M. Yao, M. Dueck, J. E. Feugate, V. Parpura, and M. Martins-Green
cCXCR1 is a receptor for cIL-8 (9E3/cCAF) and its N- and C-terminal peptides and is also activated by hIL-8 (CXCL8)
J. Leukoc. Biol., March 1, 2005; 77(3): 421 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Sun, P. Gao, L. Chen, D. Ma, J. Wang, J. J. Oppenheim, and N. Zhang
Protein Kinase C {zeta} Is Required for Epidermal Growth Factor-Induced Chemotaxis of Human Breast Cancer Cells
Cancer Res., February 15, 2005; 65(4): 1433 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-Y. Hao, D. H. Moore, P. Wong, J. L. Bennington, N. M. Lee, and L.-C. Chen
Alteration of Gene Expression in Macroscopically Normal Colonic Mucosa from Individuals with a Family History of Sporadic Colon Cancer
Clin. Cancer Res., February 15, 2005; 11(4): 1400 - 1407.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Hu, H. Sun, J. Drake, F. Kittrell, M. C. Abba, L. Deng, S. Gaddis, A. Sahin, K. Baggerly, D. Medina, et al.
From Mice to Humans: Identification of Commonly Deregulated Genes in Mammary Cancer via Comparative SAGE Studies
Cancer Res., November 1, 2004; 64(21): 7748 - 7755.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. C. Corton, U. Apte, S. P. Anderson, P. Limaye, L. Yoon, J. Latendresse, C. Dunn, J. I. Everitt, K. A. Voss, C. Swanson, et al.
Mimetics of Caloric Restriction Include Agonists of Lipid-activated Nuclear Receptors
J. Biol. Chem., October 29, 2004; 279(44): 46204 - 46212.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
N. Zhang, T. J. Rogers, M. Caterina, and J. J. Oppenheim
Proinflammatory Chemokines, Such as C-C Chemokine Ligand 3, Desensitize {micro}-Opioid Receptors on Dorsal Root Ganglia Neurons
J. Immunol., July 1, 2004; 173(1): 594 - 599.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the Society for Leukocyte Biology.